跳转至内容
Merck

1448923

USP

莫匹罗星锂

United States Pharmacopeia (USP) Reference Standard

别名:

9-((E)-4-{(2S,3R,4R,5S)-3,4-二羟基-5-[(2S,3S)-3-((1S,2S)-2-羟基-1-甲基-丙基)环氧乙烷基甲基]四氢吡喃-2-基}-3-甲基-丁-2-烯酰氧基)壬酸 锂盐, 假单胞菌酸A 锂盐

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C26H43LiO9
CAS号:
分子量:
506.56
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

mupirocin

製造商/商標名

USP

應用

pharmaceutical (small molecule)

格式

neat

SMILES 字串

[Li+].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@H]2CO[C@@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)[C@H](O)[C@@H]2O

InChI

1S/C26H44O9.Li/c1-16(13-23(30)33-11-9-7-5-4-6-8-10-22(28)29)12-20-25(32)24(31)19(15-34-20)14-21-26(35-21)17(2)18(3)27;/h13,17-21,24-27,31-32H,4-12,14-15H2,1-3H3,(H,28,29);/q;+1/p-1/b16-13+;/t17-,18-,19-,20-,21-,24+,25-,26-;/m0./s1

InChI 密鑰

XFIKMPRBSORKQP-JATHGWPISA-M

正在寻找类似产品? 访问 产品对比指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Mupirocin lithium USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Mupirocin
  • Mupirocin Calcium
  • Mupirocin Cream
  • Mupirocin Nasal Ointment
  • Mupirocin Ointment

分析報告

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

其他說明

Sales restrictions may apply.

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Erysipelas as a superinfection of an oral lymphangioma.
Iria Neri et al.
The Journal of pediatrics, 165(1), 205-205 (2014-05-06)
Christophe Camus et al.
Critical care medicine, 42(5), 1121-1130 (2013-12-25)
In a multicenter, placebo-controlled, randomized, double-blind trial, we showed that acquired infections in intubated patients were reduced by the combination of topical polymyxin plus tobramycin and nasal mupirocin plus chlorhexidine body wash. Because intubated patients are particularly at risk for

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门